You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.
In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
The Cobas HPV Test is now approved for use as a primary screening test with BD's SurePath and Hologic's ThinPrep PreservCyt Solution.
Significantly fewer women screened with HPV testing alone had high-grade pathologies four years later compared to those receiving cytology testing.
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify cervical cancer patients who may benefit from the anti-PD1 immunotherapy.
IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.
Hologic's device will potentially increase sensitivity for cervical disease detection in US laboratories that employ the firm's automated imaging system.
One outcome of a recent FDA workshop about the potential for using self-collection for Pap testing was that it might be better to do self-collection in combination with molecular testing.
BGI is also developing sequencing-based self-sampling assays for pharmacogenomics and hereditary cancer testing.